Course Description
There are high rates of substance use disorders, including opioid use disorder, in patients in the correctional system. Access to medications for OUD vary from state to state. Lack of access to treatment upon transition to the community after release has been implicated in relapse, overdose, and high rates of recidivism.
Pharmacists who care for patients with psychiatric disorders often encounter patients who have been recently released from jail/prison and who are in need of continued care for OUD.
Multiple organizations and recent publications have focused on barriers to care and the need to identify ways to successfully transition patients from the criminal justice system into society without a break in treatment to reduce negative outcomes.
Learning Objectives
- Analyze barriers to provide medications for opioid use disorder (MOUD) and consequences of the lack of access to care at time of release from incarceration.
- Evaluate the literature regarding role of subcutaneous buprenorphine and long-acting naltrexone before transition back into the community.
- Construct a pharmacotherapy plan for MOUD at time of transition from incarceration back into the community.
Target Audience
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric patients, we invite you to participate in this online course.
Faculty
View biographical information
David Dadiomov, PharmD, BCPP
Assistant Professor
University of Southern California School of Pharmacy
Los Angeles, CA
David Dadiomov, PharmD, BCPP, is a clinical assistant professor of pharmacy practice at the University of Southern California (USC). He received his PharmD from the University of Michigan College of Pharmacy. He completed his PGY1 Pharmacy Residency at Michigan Medicine, and his PGY2 Psychiatric Pharmacy Residency at University of California, San Diego, Health. He holds board certification in psychiatric pharmacy.
He is a credentialed clinical pharmacist within the LA County Department of Health Services where he provides direct patient care for individuals with mental illness, substance use disorders, experiencing homelessness, or incarcerated. He also co-manages clinical pharmacy programs within the county hospitals focused on transitions of care services. He serves as the Director for the PGY2 Psychiatric Pharmacy Residency Program at USC.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 10/06/2022
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-22-073-H08-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Planning Committee
|
Ericka Crouse, PharmD, BCPP, BCGP, FASHP, FASCP Associate Professor VCU School of Pharmacy Richmond, VA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ASHP - PAM Behavioral Health Committee (volunteer), Editorial Board - The Medical Letter (paid), American Society of Consultant Pharmacists - speak at meetings/webinars on GeroPsych topics (paid), Wolters-Kluwer, paid consultant |
|
Cassandra Davis, PharmD, BCPP, BCPS Mental Health Clinical Pharmacy Specialist Orlando VA Medical Center Orlando, FL No Relevant Financial Relationships to Disclose |
 Megan J. Ehret, PharmD, BCPP, MSBCPP Program Director Professor University of Maryland Baltimore, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Psych U Section Advisor, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH |
 Sarah Melton, PharmD, BCPP, BCACP, FASCPChair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia, Virginia Board of Pharmacy, Virginia Opioid Abatement Authority, Overmountain Recovery, Virginia Department of Health Professions Board, Virginia Medicaid Pharmacy and Therapeutics Committee |
|
Troy Moore, PharmD, MS, BCPP |
|
Erika Titus-Lay, PharmD, BCPP, BCPS Assistant Professor California Northstate University College of Pharmacy Elk Grove, CA Educational Grants, Research Grants or Contracts: Sponsor, ASHP Pharmacy Leadership Scholars Research Grant |
2022 Reviewers
|
Audrey Abelleira, PharmD, BCPP, BCPS |
|
David Dadiomov, PharmD, BCPP |
|
James J. Gasper, PharmD, BCPP |
|
Cindy A. Gutierrez, PharmD, MS, BCPP |
|
Dara L. Johnson, PharmD, BCPP, BCACP |
|
Benjamin Miskle, PharmD |
|
Marnie Noel, PharmD, BCPP |
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: CAM 2038 (Buprenorphine long-acting subcutaneous injection) for opioid use disorder
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.